NCT07564934 is a Phase 2 clinical trial of Extended Reality Exergaming in Cerebral Palsy (CP), sponsored by University of Alabama at Birmingham.

Who is sponsoring NCT07564934?

NCT07564934 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT07564934?

Interventions in NCT07564934: Extended Reality Exergaming.

What condition does NCT07564934 study?

NCT07564934 studies Cerebral Palsy (CP).

Is NCT07564934 still recruiting?

NCT07564934 is currently not yet recruiting.

Last reviewed 2026-06-10 · How we verify

NCT07564934

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilities

Not yet recruiting Phase 2

What this trial tests

Phase 2 trial testing Extended Reality Exergaming in Cerebral Palsy (CP) in 130 participants. Not yet recruiting.

Timeline

1 December 2026

31 May 2031

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	Phase 2
Status	Not yet recruiting
Enrollment	130
Start date	1 December 2026
Estimated completion	31 May 2031

Drugs / interventions tested

Extended Reality Exergaming

Conditions studied

Cerebral Palsy (CP) — all drugs for Cerebral Palsy (CP) →

Sponsor

University of Alabama at Birmingham

Who can join

Eligibility, any sex, with Cerebral Palsy (CP).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cerebral Palsy (CP)

Currently open trials in the same condition.

NCT07587476 — Constraint-induced Movement Therapy Combined With Functional Electrical Stimulation in Children With Cerebral Palsy · NA · recruiting
NCT07500896 — Effects of an Intensive Rhythmic Dance Program on Learning Skills in Children With Cerebral Palsy · recruiting
NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
NCT07377201 — Childhood Toxin Perception Survey · recruiting
NCT07311018 — Neuromuscular Electrical Stimulation and Leap Motion-Based Exercises in Cerebral Palsy · NA · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07457385 — Congenital Syphilis Treatment Trial (CONSISTENT) in Neonates · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07564934 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: recently

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07564934.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing